The most common mutations in these tumors include loss-of-function mutations in PTCH and SUFU, gain-of-function mutation in SMO, or gene amplifications in GLI1 and GLI2, as shown in mouse or human cancers, resulting in uncontrolled Hh activity and promoting tumorigenesis (57, 58). The gene discussed is SUFU; the disease is cancer.